Method of reducing gastrointestinal side effects associated with orlistat treatment

• US 6,756,364 B2
• Filed: 07/25/2001
• Issued: 06/29/2004
• Est. Priority Date: 07/28/2000
• Status: Expired due to Term

• Current Assignee: Cheplapharm Arzneimittel GmbH
• Original Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Inventors: Hadvary, Paul, Lengsfeld, Hans, Barbier, Pierre
• Primary Examiner(s): Peselev, Elli
• Application Number:
  US09/912,957
• Publication Number:
  US 20020035089A1
• Time in Patent Office: 1,070 Days
• Field of Search: 424/439, 514/54, 514/56, 514/57, 514/58, 514/169, 514/449
• US Class Current: 514/57
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 31/716 Glucans
• CPC Class Codes: A61K 31/717 Celluloses
• CPC Class Codes: A61K 31/721 Dextrans
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.

Claims

1. A method of reducing the gastrointestinal side effects associated with orlistat treatment, which comprises administering to a patient being treated with orlistat an amount of a bile salt sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β

-cyclodextrin, γ

-cyclodextrin, guanidinoethylcellulose, and DEAE-Sephadex, effective to reduce the side effects associated with the orlistat treatment.